The Non-Hodgkin Lymphoma diagnostics market is on a steady upward trajectory, moving toward a valuation of nearly USD 24 billion by 2032. The shift toward personalized medicine ensures that diagnostics are no longer just a "yes/no" tool for cancer, but a comprehensive roadmap for treatment. With the entry of liquid biopsy and AI-enhanced imaging, the industry is poised to significantl... https://www.databridgemarketresearch.com/reports/global-non-hodgkin-lymphoma-diagnostics-market